08/03/2026
Ανακοίνωση έγκρισης θεραπείας με βλαστοκύτταρα για τη νόσο Parkinson: Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan | Sumitomo Pharma
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Toru Kimura; “Sumitomo Pharma”) and RACTHERA Co., Ltd. (Head Office: Chuo‑ku, Tokyo, Japan; President and CEO: Atsushi Ikeda; “RACTHERA”) announce that Sumitomo Pharma has obtained, as of March 6, 2026, conditional an...